Glucagon: difference between revisions
Diff·revision 9 → 10·14:43, 24 Nov 2024
Difference between revision 9 and revision 10 of Glucagon. 7 lines changed; the page grew by 590 bytes.
| Revision 9 — 12:06, 1 Nov 2024 TirzTaxonomist (talk) give the isoelectric point with the method it was determined by 4,197 bytes +83 | Revision 10 — 14:43, 24 Nov 2024 DulaglutideDug (talk) space between number and unit per PP:MOS 4,787 bytes +590 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Glucagon | 2 | | name = Glucagon |
| + | 3 | | subtitle = Pancreatic hormone | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | Source = Pancreatic islet alpha cell | 5 | | Source = Pancreatic islet alpha cell |
| ⋮ | ⋮ | ||
| 10 | | Monoisotopic mass = ≈3,483 Da | 11 | | Monoisotopic mass = ≈3,483 Da |
| 11 | | Plasma half-life = 4–6 minutes | 12 | | Plasma half-life = 4–6 minutes |
| + | 13 | <!-- Principal actions --> | |
| + | 14 | | Liver = Glycogenolysis, gluconeogenesis | |
| + | 15 | | Adipose = Lipolysis | |
| + | 16 | | Whole body = Increased energy expenditure | |
| 12 | }} | 17 | }} |
| 13 | {{hatnote|For the precursor from which glucagon is derived, see [[Proglucagon]].}} | 18 | {{hatnote|For the precursor from which glucagon is derived, see [[Proglucagon]].}} |
| ⋮ | ⋮ | ||
| 28 | == Receptor and signalling == | 33 | == Receptor and signalling == |
| 29 | The glucagon receptor is a class B GPCR with the same two-domain architecture as the [[GLP-1 receptor]] and roughly 45% sequence identity to it in the transmembrane region. It couples principally to G<sub>s</sub>; hepatic cAMP activates protein kinase A, which phosphorylates glycogen phosphorylase kinase and the transcriptional machinery driving gluconeogenic gene expression.{{r|sandoval2015}} | 34 | The glucagon receptor is a class B GPCR with the same two-domain architecture as the [[GLP-1 receptor]] and roughly 45% sequence identity to it in the transmembrane region. It couples principally to G<sub>s</sub>; hepatic cAMP activates protein kinase A, which phosphorylates glycogen phosphorylase kinase and the transcriptional machinery driving gluconeogenic gene expression.{{r|sandoval2015}} |
| + | 35 | ||
| + | 36 | The receptor relatedness is what makes multi-receptor agonism chemically tractable, and it also makes selectivity a design constraint rather than a given: an unmodified glucagon analogue has appreciable activity at the GLP-1 receptor and vice versa. Reported potency ratios for the multi-receptor peptides are assay-dependent and should be compared only within a single publication's system.{{r|coskun2022}} | |
| 30 | 37 | ||
| 31 | == References == | 38 | == References == |